Zacks Investment Research upgraded shares of NewLink Genetics (NASDAQ:NLNK) from a hold rating to a buy rating in a research note published on Saturday, Zacks.com reports. Zacks Investment Research currently has $2.00 price target on the biotechnology company’s stock.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Separately, ValuEngine upgraded NewLink Genetics from a sell rating to a hold rating in a report on Thursday, August 1st.
NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.02. The company had revenue of $0.15 million during the quarter. NewLink Genetics had a negative return on equity of 33.23% and a negative net margin of 6,587.56%. On average, sell-side analysts anticipate that NewLink Genetics will post -0.03 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of NLNK. Pennsylvania Trust Co bought a new position in NewLink Genetics during the first quarter worth about $48,000. Virtu Financial LLC bought a new position in NewLink Genetics during the first quarter worth about $60,000. Two Sigma Advisers LP grew its holdings in NewLink Genetics by 22.6% during the fourth quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 20,300 shares during the period. Requisite Capital Management LLC bought a new position in NewLink Genetics during the second quarter worth about $185,000. Finally, Bank of New York Mellon Corp grew its holdings in NewLink Genetics by 20.8% during the fourth quarter. Bank of New York Mellon Corp now owns 145,832 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 25,084 shares during the period. Institutional investors and hedge funds own 34.12% of the company’s stock.
About NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
See Also: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.